|
|
五味子酯甲和索拉非尼联合用药对晚期肝细胞癌耐药的疗效研究
|
Abstract:
索拉非尼(Sorafenib, So)作为一种治疗晚期肝癌的新型多靶向性一线口服药物，通过抑制酪氨酸酶达到一个良好的治疗效果，能够有效地提高患者的生活质量，延长生存时间。不过从疗效看，索拉非尼因口服生物利用度低、患者存在异质性及耐药性，使其一线治疗的中后期效果不理想。而五味子酯甲(Schisantherin A, SCA)作为抗癌药中的一种，能够通过抑制磷脂酰肌醇3-激酶/蛋白激酶B (PI3K/Akt)信号通路来抑制肺癌细胞的生长和转移，有望改善肝癌细胞对索拉非尼的耐药性，两者联用能否逆转耐药细胞对So的耐药，增强其敏感性，这对填补肝癌二线治疗的大量空白具有重要的临床意义。
Sorafenib (So) is a new multi-targeted first-line oral drug for the treatment of advanced hepatocellular carcinoma, which achieves a good therapeutic effect by inhibiting tyrosinase enzymes and can effectively improve patients’ quality of life and prolong survival time. However, the low oral bioavailability, patient heterogeneity and drug resistance have made sorafenib less effective in the middle and late stages of first-line treatment. Schisantherin A (SCA), one of the anti-cancer drugs, inhibits the growth and metastasis of lung cancer cells by inhibiting the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signalling pathway, which is expected to improve the resistance of liver cancer cells to sorafenib. Whether the combination of the two can reverse the resistance of drug-resistant cells to So and enhance their sensitivity has important clinical implications for filling a large number of gaps in the second-line treatment of hepatocellular carcinoma.
| [1] | 张劲远, 张银旭, 张俊华. PI3K-Akt信号通路对人大肠癌HCT-8/FU耐药细胞P-GP表达和耐药性的影响[J]. 东南大学学报院(医学版), 2013, 32(2): 169-172. |
| [2] | 刘传铃, 王佳贺. 中药抗耐药铜绿假单胞菌机制的研究进展[J]. 中国医药导报, 2019, 16(3): 40-43. |
| [3] | 洪望龙, 郑淼淼, 马国强, 等. 瑞戈非尼治疗经索拉非尼治疗失败后的肝细胞癌的经济性[J]. 中国药房, 2023, 34(8): 968-973. |
| [4] | 刘思莹, 徐丹, 张玲, 等. 基于科学知识图谱的五味子研究进展与前沿分析[J]. 中国中医药图书情报杂志, 2023, 47(3): 95-102. |
| [5] | Chen, Z. and Ye, S.Y. (2022) Research Progress on Antiviral Constituents in Traditional Chinese Medicines and Their Mechanisms of Action. Pharmaceutical Biology, 60, 1063-1076. https://doi.org/10.1080/13880209.2022.2074053 |
| [6] | Feng, F., Pan, L., Wu, J., Liu, M., He, L., Yang, L. and Zhou, W. (2022) Schisantherin A Inhibits Cell Proliferation by Regulating Glucose Metabolism Pathway in Hepatocellular Carcinoma. Frontiers in Pharmacology, 13, Article ID: 1019486.
https://doi.org/10.3389/fphar.2022.1019486 |
| [7] | 付亚东, 陈佳美, 刘伟, 等. 五味子酯甲对肝脏药物代谢酶的调节及药理作用的研究进展[J]. 中药新药与临床药理, 2020, 31(6): 741-748. https://doi.org/10.19378/j.issn.1003-9783.2020.06.019 |
| [8] | Xu, K., et al. (2010) Schisantherin A Exhibits Anti-Inflammatory Properties by Down-Regulating NF-κB and MAPK Signaling Pathways in Lipopolysaccharide-Treated RAW 264.7 Cells. Inflammation, 33, 126-136.
https://doi.org/10.1007/s10753-009-9166-7 |
| [9] | Costa, R., Han, H.S. and Gradishar, W.J. (2018) Targeting the PI3K/AKT/mTOR Pathway in Triple-Negative Breast Cancer: A Review. Breast Cancer Research and Treatment, 169, 397-406. https://doi.org/10.1007/s10549-018-4697-y |
| [10] | Llovet, J.M., Pe？a, C.E., Lathia, C.D., Shan, M., Meinhardt, G., Bruix, J. and SHARP Investigators Study Group (2012) Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 18, 2290-2300. https://doi.org/10.1158/1078-0432.CCR-11-2175 |
| [11] | 陈翔, 温迪光, 游逾, 等. 铁死亡在索拉非尼治疗肝癌中的作用及机制[J]. 临床肝胆病杂志, 2019, 35(10): 2316-2319. |
| [12] | 杨蕙华, 陈大红, 刁文婧, 等. G6PD调控PI3K/Akt信号通路诱导肝癌细胞索拉非尼耐药的机制研究[J]. 中国药房, 2022, 33(19): 2338-2342. |
| [13] | 杜若昕, 郭欣燕, 张伟, 等. 肝细胞癌中索拉非尼耐药性机制的研究进展[J]. 河北医科大学学报, 2022, 43(9): 1091-1095. |
| [14] | 谭晖, 王吉昌, 董丹凤, 等. 五味子酯甲通过抑制CCAT1和PI3K-AKT信号通路抑制肺癌细胞的迁移和侵袭[J]. 世界中医药, 2021, 16(13): 1966-1971. |
| [15] | 张吉超, 邹磊, 李道堂. 肺癌肝转移治疗的研究进展[J]. 中国现代普通外科进展, 2014, 17(3): 246-248. |
| [16] | Ying, X., Ma, N., Zhang, X., Guo, H., Liu, Y., Chen, B., Zhao, S., et al. (2021) Research Progress on the Molecular Mechanisms of Hepatic Metastasis in Lung Cancer: A Narrative Review. Annals of Palliative Medicine, 10, 4806-4822.
https://doi.org/10.21037/apm-20-1675 |
| [17] | Yin, L., Liu, X., Shao, X., Feng, T., Xu, J., Wang, Q. and Hua, S. (2021) The Role of Exosomes in Lung Cancer Metastasis and Clinical Applications: An Updated Review. Journal of Translational Medicine, 19, Article No. 312.
https://doi.org/10.1186/s12967-021-02985-1 |
| [18] | Lin, Q., Ling, Y.B., Chen, J.W., et al. (2018) Circular RNA circCDK13 Suppresses Cell Proliferation, Migration and Invasion by Modulating the JAK/STAT and PI3K/Akt Pathways in Liver Cancer. International Journal of Oncology, 53, 246-256. https://doi.org/10.3892/ijo.2018.4371 |
| [19] | Cao, B., Liu, C. and Yang, G. (2018) RETRACTED: Down-Regulation of lncRNA ADAMTS9-AS2 Contributes to Gastric Cancer Development via Activation of PI3K/Akt Pathway. Biomedicine & Pharmacotherapy, 107, 185-193.
https://doi.org/10.1016/j.biopha.2018.06.146 |
| [20] | Wang, S., Lei, Y., Cai, Z., et al. (2018) Girdin Regulates the Proliferation and Apoptosis of Pancreatic Cancer Cells via the PI3K/Akt Signalling Pathway. Oncology Reports, 40, 599-608. https://doi.org/10.3892/or.2018.6469 |
| [21] | Yao, H., Su, S., Xia, D., et al. (2018) F-Box and Leucine-Rich Repeat Protein 5 Promotes Colon Cancer Progression by Modulating PTEN/PI3K/Akt Signaling Pathway. Biomedicine & Pharmacotherapy, 107, 1712-1719.
https://doi.org/10.1016/j.biopha.2018.08.119 |
| [22] | Fujita, T., Washio, K., Takabatake, D., et al. (2005) Proteasome Inhibitors Can Alter the Signaling Pathways and Attenuate the P-Glycoprotein-Mediated Multidrug Resistance. International Journal of Cancer, 117, 670-682.
https://doi.org/10.1002/ijc.21063 |
| [23] | Shinoda, C., et al. (2005) Doxorubicin Induces Expression of Multidrug Resistance-Associated Protein 1 in Human Small Cell Lung Cancer Cell Lines by the c-Jun N-Terminal Kinase Pathway. International Journal of Cancer, 117, 21-31. https://doi.org/10.1002/ijc.21094 |
| [24] | 小燕, 蔡晓军, 类建翔, 等. PI-3K/Akt抑制剂LY294002对卵巢癌细胞A2780/Taxol多药耐药性的逆转作用[J]. 癌症, 2008, 27(4): 343-347. |
| [25] | 李如佳, 戴园园, 覃春, 等. 中西医结合根治耐药幽门螺杆菌的方法分析[J]. 中华临床医师杂志(电子版), 2021, 15(9): 716-720. |
| [26] | Choi, B.H., Kim, C.G., Lim, Y., et al. (2008) Curcumin Down-Regulates the Multidrug-Resistance mdr1b Gene by Inhibiting the PI3K/Akt/NF Kappa B Pathway. Cancer Letters, 259, 111-118.
https://doi.org/10.1016/j.canlet.2007.10.003 |
